[Safety of specific cyclo-oxygenase 2 inhibitors].
Verheugt
F W
FW
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced / Q000517:prevention & control*; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D009288:Naproxen; D001241:Aspirin